Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Update on calcium-channel blocking agents.

R L Talbert, H I Bussey

    Clinical Pharmacy
    |September 1, 1983
    PubMed
    Summary
    This summary is machine-generated.

    This review examines calcium-channel blockers like verapamil, nifedipine, and diltiazem for various heart conditions. Diltiazem shows the best side-effect profile, making these drugs valuable reserve agents for angina and hypertension.

    Related Concept Videos

    You might also read

    Related Articles

    Articles linked to this work by shared authors, journal, and citation graph.

    Sort by
    Same author

    A consensus conference on complex biologics and low molecular weight heparins.

    International angiology : a journal of the International Union of Angiology·2010
    Same author

    Dietary supplement use among anticoagulation clinic patients.

    Journal of thrombosis and haemostasis : JTH·2007
    Same author

    Antiplatelet therapy in secondary stroke prevention.

    Expert opinion on pharmacotherapy·2002
    Same author

    A call for pharmacists to improve the care of patients with myocardial infarction.

    Pharmacotherapy·2001
    Same author

    Managing excessive warfarin anticoagulation.

    Annals of internal medicine·2001
    Same author

    Antithrombotic therapy in patients with mechanical and biological prosthetic heart valves.

    Chest·2001
    Same journal

    Criteria for use of epoetin alfa in adult cancer and orthopedic-surgery patients.

    Clinical pharmacy·1993
    Same journal

    Accuracy of unbound-quinidine concentration determination after ultrafiltration.

    Clinical pharmacy·1993
    Same journal

    Modified Michaelis-Menten equation for estimating unbound-phenytoin concentrations.

    Clinical pharmacy·1993
    Same journal

    Predicting vancomycin pharmacokinetics by using aminoglycoside pharmacokinetics.

    Clinical pharmacy·1993
    Same journal

    Efficacy of nutritional supplements used by athletes.

    Clinical pharmacy·1993
    Same journal

    Low-molecular-weight heparins for the treatment of deep-vein thrombosis.

    Clinical pharmacy·1993
    See all related articles

    Area of Science:

    • Cardiology
    • Pharmacology

    Background:

    • Calcium-channel blockers (CCBs) are a class of drugs used to treat cardiovascular conditions.
    • Verapamil, nifedipine, and diltiazem are three commonly used CCBs with distinct pharmacokinetic and clinical profiles.

    Purpose of the Study:

    • To review the pharmacokinetics, clinical efficacy, and adverse effects of verapamil, nifedipine, and diltiazem.
    • To compare the safety and effectiveness of these three CCBs across various cardiovascular indications.

    Main Methods:

    • Systematic review of existing literature on verapamil, nifedipine, and diltiazem.
    • Analysis of pharmacokinetic data, including absorption, metabolism, and protein binding.
    • Evaluation of clinical trial data for efficacy in conditions such as supraventricular tachycardia, myocardial ischemia, angina, cardiomyopathy, and hypertension.

    Related Experiment Videos

    Main Results:

    • All three CCBs are well-absorbed orally but undergo significant first-pass metabolism.
    • Verapamil is a first-choice for acute paroxysmal supraventricular tachycardia (PSVT); CCBs show promise for angina, cardiomyopathy, and hypertension.
    • Diltiazem has the most favorable side-effect profile, with lower discontinuation rates compared to verapamil and nifedipine.

    Conclusions:

    • Calcium-channel blockers are effective agents for specific cardiovascular conditions, particularly as reserve therapies.
    • Diltiazem offers a superior safety profile among the reviewed CCBs.
    • CCBs play a significant role in managing exertional and variant angina, cardiomyopathy, and hypertension, with careful consideration of their side effects.